New Low-Addiction Opioid Shows Promise in Lab Tests

Researchers have identified a new opioid compound that provides effective pain relief in laboratory rats while showing significantly lower potential for addiction compared to morphine, according to a study published in the journal Neuropsychopharmacology on April 18, 2026.

The experimental drug, designated as CB-18, was developed by a team at the Scripps Research Institute in La Jolla, California, with the goal of separating the analgesic properties of opioids from their addictive side effects. In controlled experiments, rats administered CB-18 demonstrated comparable pain suppression to those given morphine when subjected to thermal and mechanical pain tests. However, when given the opportunity to self-administer the drug—a standard behavioral measure of addiction liability in preclinical studies—the animals showed markedly reduced interest in CB-18 compared to morphine.

According to the study’s lead author, Dr. Laura Chen, a neuropharmacologist at Scripps Research, the findings suggest that CB-18 activates pain-relieving pathways in the brain and spinal cord without strongly engaging the neural circuits associated with reward and dependence. “We observed robust analgesia at doses that did not trigger significant dopamine release in the nucleus accumbens, a key brain region involved in the reinforcing effects of drugs,” Dr. Chen explained in a press release accompanying the study. “This dissociation between pain relief and reward activation is what we’ve been aiming for in opioid development for decades.”

The research team used a combination of pharmacological assays, genetic knockdown models, and real-time neural imaging to trace CB-18’s mechanism of action. Unlike traditional opioids such as morphine, fentanyl, or oxycodone—which primarily activate the mu-opioid receptor (MOR) in ways that strongly stimulate the mesolimbic dopamine pathway—CB-18 appears to act as a “biased agonist” at the MOR. This means it selectively triggers G-protein signaling pathways linked to pain inhibition while minimizing activation of beta-arrestin pathways, which are more closely associated with tolerance, respiratory depression, and addictive behaviors.

In addition to reduced self-administration, rats treated with CB-18 exhibited fewer signs of withdrawal when the drug was discontinued, including lower incidence of jumping, teeth chattering, and weight loss—common indicators of physical dependence in rodent models. The drug also did not produce the characteristic hyperlocomotion seen with morphine, suggesting less stimulation of the brain’s reward system.

While the results are promising, experts caution that findings in animal models do not always translate to humans. Dr. Marcus Ortiz, a pain management specialist at the Mayo Clinic not involved in the study, emphasized the importance of cautious interpretation. “Preclinical studies like this are essential for early-stage drug discovery, but they cannot predict human outcomes with certainty,” he said. “Many compounds that show reduced addiction liability in rodents have failed to demonstrate the same advantage in clinical trials, either due to insufficient efficacy or unforeseen side effects in people.”

The researchers acknowledge that CB-18 is still in the early phases of development. Next steps include further toxicology studies, pharmacokinetic analysis, and eventual Phase I clinical trials to assess safety in healthy human volunteers. If those trials proceed successfully, larger studies would be needed to evaluate the drug’s effectiveness in treating acute and chronic pain conditions, as well as its long-term risks.

According to the Centers for Disease Control and Prevention (CDC), opioid-related overdose deaths remain a leading cause of injury-related mortality in the United States, with synthetic opioids like fentanyl driving much of the recent increase. While prescription opioids such as morphine and oxycodone are still used medically for severe pain, their potential for misuse and addiction continues to pose significant public health challenges. A safer alternative that maintains analgesic efficacy without high addiction risk could represent a meaningful advance—if proven effective and safe in humans.

As of now, CB-18 is not approved for medical use, and no timeline for human testing has been publicly announced. The study was funded by grants from the National Institutes of Health (NIH) and the Brain & Behavior Research Foundation. All animal procedures were conducted in accordance with guidelines from the Institutional Animal Care and Use Committee (IACUC) at Scripps Research.